The ONCOCAMP Study

Condition(s) studied

Investigational drug(s) / intervention(s)

Data collection (retrospective): Collection of patient data entered in the ROC platform from the beginning activation of the platform (November 2018) until the date on which the study is approved by the local ethics committee

Data collection (prospective): Collection of patient data entered in the ROC platform from the date in which the study is approved by the local ethical committee

Study summary

The present study is a retrospective-prospective observational and multicentric study aiming to collect data relating to all patients included in the ROC platform. All ROC centers will be involved in the present study.

Eligibility

Primary outcome measure(s)

• Incidence for each tumor of the patients included in the ROC platform — Every year up to 5 years
  Incidence for each tumor of the patients included in the ROC platform
• Evaluation of the time interval between GOM activities — Every 6 months up to 3 years
  Time interval between reporting and taking charge by the GOM, the date diagnosis and the GOM meeting date, the first GOM meeting and the final therapeutic decision, the therapy decision and the therapeutic act, and the request for home assistance and the actual taking in charge by the ASL
• Evaluation of the time interval between GOM activities — Every 6 months up to 3 years
  Time interval between the request for home assistance and the actual taking in charge by the ASL
• Evaluation of the time interval between GOM activities — Every 6 months up to 3 years
  Time interval between the therapy decision and the therapeutic act
• Evaluation of the time interval between GOM activities — Every 6 months up to 3 years
  Time interval between the first GOM meeting and the final therapeutic decision
• Evaluation of the time interval between GOM activities — Every 6 months up to 3 years
  Time interval betweenthe date diagnosis and the GOM meeting date
• Frequency of use of the services of the ROC platform — Every 2 months up to 5 years
  Frequency of use of the services of the ROC platform
• Descriptive analysis of each subgroup of patients (subdivision by tumor type) — Every 6 months up to 5 years
  Descriptive analysis of each subgroup of patients (subdivision by tumor type)
• Spatial analysis for each patient — Every year up to 5 years
  Spatial analysis for each patient
• Frequency of adherence to guidelines of the Diagnostic Therapeutic Assistance Paths (PDTA) — Every 6 months up to 5 years
  Frequency of adherence to guidelines of the Diagnostic Therapeutic Assistance Paths (PDTA)
• Percentage of patient included in clinical trial — Every 2 months up to 5 years
  Percentage of patient included in clinical trial
• Assessment of costs arising due to inefficiencies (repetition and inappropriateness of diagnostic tests; passive health mobility rate — Every 6 months up to 5 years
  Assessment of costs arising due to inefficiencies (repetition and inappropriateness of diagnostic tests; passive health mobility rate
• Prevalence for each tumor of the patients included in the ROC platform — Every year up to 5 years
  Prevalence for each tumor of the patients included in the ROC platform

Trial sites (17)

More National Cancer Institute, Naples trials in Italy

Other trials for the same condition